Drug Type CAR-T |
Synonyms Targeted CD19/BCMA CAR-T Therapy( Nanjing Bioheng Biotech), RD06-05 |
Target |
Mechanism BCMA modulators(B-cell maturation protein modulators), CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 1 | CN | 15 Jan 2025 | |
Idiopathic Inflammatory Myopathies | Phase 1 | CN | 15 Jan 2025 | |
Multiple Sclerosis | Phase 1 | CN | 15 Jan 2025 | |
Neuromyelitis Optica | Phase 1 | CN | 15 Jan 2025 | |
Scleroderma, Systemic | Phase 1 | CN | 15 Jan 2025 | |
Systemic Lupus Erythematosus | Phase 1 | CN | 15 Jan 2025 |